---
created: '2026-02-13T17:51:33.588526Z'
description: A multifunctional ectoenzyme that is the primary NAD+ consuming enzyme
  in mammals. Functions as NAD+ glycohydrolase, degrading NAD+ and contributing to
  age-related NAD+ decline. Also involved in calcium signaling and immune cell regulation.
dg-home: false
dg-publish: true
gardenUsername: dev_admin
permalink: /garden/dev_admin/protein/cd38/
slug: cd38
tags:
- protein
- enzyme
- nad_consumer
- aging
- immune_system
- calcium_signaling
templateEngineOverride: njk
title: CD38
type: protein
updated: '2026-02-13T17:51:33.588526Z'
---

{% raw %}
<h1>CD38</h1>
<h2>Overview</h2>
<p>CD38 is a type II transmembrane glycoprotein that functions as the major NAD+ consuming enzyme in mammalian tissues. Originally identified as a lymphocyte differentiation antigen, CD38 has emerged as a critical regulator of NAD+ homeostasis and a key contributor to age-related NAD+ decline.</p>
<p>CD38's NAD+ consuming activity has profound implications for aging and metabolic health. Studies show that CD38 expression and activity increase with age and inflammation, driving down NAD+ levels and consequently reducing sirtuin activity. Inhibiting CD38 has become a promising strategy for restoring youthful NAD+ levels.</p>
<p>Beyond NAD+ metabolism, CD38 plays important roles in immune cell signaling, calcium mobilization, and has emerged as a therapeutic target in multiple myeloma treatment.</p>
<h2>Mechanism of Action</h2>
<h3>Enzymatic Activities</h3>
<p>CD38 has multiple enzymatic activities:</p>
<ol>
<li><strong>NAD+ Glycohydrolase</strong>: NAD+ → Nicotinamide + ADP-ribose (primary activity)</li>
<li><strong>ADP-ribosyl Cyclase</strong>: NAD+ → Cyclic ADP-ribose (cADPR)</li>
<li><strong>cADPR Hydrolase</strong>: cADPR → ADP-ribose</li>
</ol>
<h3>NAD+ Consumption</h3>
<ul>
<li><strong>High Catalytic Rate</strong>: ~100 NAD+ molecules/second</li>
<li><strong>Major NAD+ Consumer</strong>: Accounts for majority of cellular NAD+ degradation</li>
<li><strong>Age-Dependent Increase</strong>: Expression rises with age and inflammation</li>
<li><strong>Senescence-Associated</strong>: Increased in senescent cells (SASP component)</li>
</ul>
<h3>Calcium Signaling</h3>
<ul>
<li>cADPR production mobilizes calcium from ER stores</li>
<li>Important for immune cell activation</li>
<li>Regulates insulin secretion in pancreatic beta cells</li>
</ul>
<h2>Role in Aging</h2>
<h3>Age-Related NAD+ Decline</h3>
<ul>
<li>CD38 expression increases 2-3 fold with age in multiple tissues</li>
<li>Contributes to ~50% reduction in NAD+ levels seen in aged tissues</li>
<li>Driven by chronic low-grade inflammation (inflammaging)</li>
<li>CD38 knockout mice maintain youthful NAD+ levels</li>
</ul>
<h3>Senescent Cell Involvement</h3>
<ul>
<li>Senescent cells express high CD38</li>
<li>Part of senescence-associated secretory phenotype (SASP)</li>
<li>Inflammatory cytokines (TNF-α, IL-6) upregulate CD38</li>
<li>Creates vicious cycle of inflammation → CD38 → low NAD+ → dysfunction</li>
</ul>
<h2>Clinical Significance</h2>
<h3>Therapeutic Targeting</h3>
<p><strong>CD38 Inhibitors for NAD+ Restoration</strong>:</p>
<ul>
<li>Apigenin (natural flavonoid)</li>
<li>Quercetin (natural flavonoid)</li>
<li>78c (synthetic inhibitor)</li>
<li>Luteolinidin</li>
</ul>
<p><strong>Anti-CD38 Antibodies (Cancer)</strong>:</p>
<ul>
<li>Daratumumab (multiple myeloma)</li>
<li>Isatuximab (multiple myeloma)</li>
</ul>
<h3>Disease Associations</h3>
<ul>
<li><strong>Multiple Myeloma</strong>: CD38 overexpressed, therapeutic target</li>
<li><strong>Metabolic Syndrome</strong>: CD38-driven NAD+ decline contributes</li>
<li><strong>Neurodegeneration</strong>: CD38 inhibition protective in models</li>
<li><strong>Cardiac Aging</strong>: CD38 contributes to age-related cardiac dysfunction</li>
</ul>
<h2>Research Highlights</h2>
<ul>
<li><strong>Camacho-Pereira et al., 2016</strong> (PMID: 27304503): Demonstrated CD38 as major driver of age-related NAD+ decline</li>
<li><strong>Tarrago et al., 2018</strong> (PMID: 30111835): CD38 inhibitor 78c reversed NAD+ decline in aged mice</li>
<li>CD38 knockout mice show preserved NAD+ and improved healthspan</li>
</ul>
<!-- NEO4J_CONTENT_START -->
<h2>Relationships</h2>
<p>No relationships found.</p>
<!-- NEO4J_CONTENT_END -->
<h2>Relationships</h2>
<p>CONSUMES::<a class="internal-link is-unresolved" href="/404">NAD+</a> - Primary NAD+ degrading enzyme<br />
INHIBITED_BY::<a href="/garden/dev_admin/supplement/quercetin/" class="internal-link">Quercetin</a> - Natural CD38 inhibitor<br />
INHIBITED_BY::<a href="/garden/dev_admin/supplement/apigenin/" class="internal-link">Apigenin</a> - Natural flavonoid inhibitor<br />
CONTRIBUTES_TO::<a class="internal-link is-unresolved" href="/404">Aging</a> - Driver of age-related NAD+ decline<br />
ACTIVATED_BY::<a href="/garden/dev_admin/pathway/nf-kb-pathway/" class="internal-link">NF-kB Pathway</a> - Inflammatory signaling increases expression<br />
RELATED_TO::<a href="/garden/dev_admin/protein/sirt1/" class="internal-link">SIRT1</a> - Competes for NAD+ substrate<br />
RELATED_TO::<a href="/garden/dev_admin/protein/sirt3/" class="internal-link">SIRT3</a> - Competes for NAD+ substrate<br />
AFFECTS_ORGAN::<a class="internal-link is-unresolved" href="/404">Brain</a> - Neurological effects of NAD+ depletion<br />
PARTICIPATES_IN_PATHWAY::<a href="/garden/dev_admin/pathway/nad-salvage-pathway/" class="internal-link">NAD+ Salvage Pathway</a> - Major NAD+ consumer<br />
ENCODED_BY::<a href="/garden/dev_admin/protein/cd38/" class="internal-link">CD38</a> - CD38 gene</p>
<h2>References</h2>
<ul>
<li>Camacho-Pereira J, et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metab. 2016;23(6):1127-39. PMID: 27304503</li>
<li>Tarragó MG, et al. A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. Cell Metab. 2018;27(5):1081-1095.e10. PMID: 29719225</li>
<li>Chini EN. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. Curr Pharm Des. 2009;15(1):57-63. PMID: 19149603</li>
<li>Hogan KA, et al. The Multi-faceted Ecto-enzyme CD38: Roles in Immunomodulation, Cancer, Aging, and Metabolic Diseases. Front Immunol. 2019;10:1187. PMID: 31214161</li>
</ul>

{% endraw %}